USC study finds exposure to “forever chemical” PFAS linked to liver cancer in humans

Imfinzi regimen reduces the risk of disease progression or death in liver cancer eligible for embolization

Positive results from the EMERALD-1 phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival compared to TACE alone in patients with hepatocellular carcinoma eligible for embolization.

March 29, 2024

Vol.50 No.13

Clinical Roundup

USC researchers find genetic variant contributing to disparities in childhood leukemia risk

Researchers from the University of Southern California found a genetic variant contributing to disparities in childhood leukemia risk. The variant, located on the IKZF1 gene, helps explain why Hispanic/Latino children face a higher risk of acute lymphoblastic leukemia and offers insights about what causes the disease.

March 29, 2024

Vol.50 No.13

Clinical Roundup

UC Davis study: TB vaccine shrinks liver cancer tumors in mice

A UC Davis Health study found that a single dose of Bacillus Calmette-Guérin, or BCG, the vaccine for tuberculosis, reduced liver tumor burden and extended the survival of mice with liver cancer. The study, published in Advanced Science, is the first to show the promising effects of the vaccine in treating liver cancer.

March 08, 2024

Vol.50 No.10

Clinical Roundup

Cedars-Sinai study finds two key proteins could help protect the liver from cancerous cells

Cedars-Sinai investigators have discovered how the liver defends itself against cancer. Their study, published in the peer-reviewed Journal of Hepatology, suggests targets for therapies to protect the liver both from cancers that originate there and cancers that spread to the liver from other parts of the body.

December 15, 2023

Vol.49 No.46

Clinical Roundup

Discovery at Purdue points to new approach to treating liver cancer

A study of the relationship between the enzyme DDX5, liver cancer and sorafenib, published in the Nature journal Cell Death & Disease points to the potential for a more effective therapy that combines existing anti-cancer drugs with treatments that spur production of this enzyme.

December 08, 2023

Vol.49 No.45

Clinical Roundup

Liver cancer rates are rising with each successive generation of Mexican Americans, study finds

Recent research reveals that with each subsequent generation of Mexican Americans, the risk of developing liver cancer has climbed.

December 01, 2023

Vol.49 No.44

USC study finds exposure to “forever chemical” PFAS linked to liver cancer in humans

YOU MAY BE INTERESTED IN

Imfinzi regimen reduces the risk of disease progression or death in liver cancer eligible for embolization

USC researchers find genetic variant contributing to disparities in childhood leukemia risk

UC Davis study: TB vaccine shrinks liver cancer tumors in mice

Cedars-Sinai study finds two key proteins could help protect the liver from cancerous cells

Discovery at Purdue points to new approach to treating liver cancer

Liver cancer rates are rising with each successive generation of Mexican Americans, study finds

Renew today!

Subscriber content

Login